Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.64 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262412 | 0.90 | SMO (0.64) | SMODGAT1MAPTTP53 | |
| SCHEMBL4261440 | 0.90 | SMO (0.74) | SMODGAT1TRPV1TP53 | |
| SCHEMBL4254381 | 0.88 | SMO (0.69) | SMODGAT1TRPV1MAPT | |
| SCHEMBL4260410 | 0.87 | SMO (0.68) | SMODGAT1TRPV1MAPT | |
| SCHEMBL4263809 | 0.87 | SMO (0.74) | SMODGAT1TRPV1MAPT | |
| SCHEMBL4263832 | 0.86 | SMO (0.64) | SMODGAT1TRPV1MAPTTP53 | |
| SCHEMBL4257547 | 0.85 | SMO (0.69) | SMODGAT1TRPV1MAPTHDAC6 | |
| SCHEMBL4252955 | 0.84 | SMO (0.64) | SMODGAT1TRPV1NAMPTTP53 | |
| SCHEMBL4256983 | 0.83 | SMO (0.63) | SMODGAT1TRPV1MAPT | |
| SCHEMBL4263798 | 0.82 | SMO (0.61) | SMODGAT1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | claimed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | OXA1L, CYP11B2, CYP3A7 | SMO 1063/4885DGAT1 2723/4885TRPV1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.